{"transactions":[{"id":719817,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33406,"kind":"person","name":"Bradsher Neal C","position":1,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"OPTION TO PURCHASE COMMON SHARES","published_at":"2026-07-02T21:33:23.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable on the earlier of: (a) July 1, 2027 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the \"Issuer\") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the \"Reporting Person\") continuous service with the Issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"COMMON SHARES","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000919574-26-004259","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957426004259/ownership.xml","form_type":"4"}},{"id":719818,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:41.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294873","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294873/ownership.xml","form_type":"4"}},{"id":719816,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:38.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294871/ownership.xml","form_type":"4"}},{"id":719814,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":22606,"kind":"person","name":"ANDREWS DEBORAH J","position":1,"cik":"0001325697","reported_name":"ANDREWS DEBORAH J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:23.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294860","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294860/ownership.xml","form_type":"4"}},{"id":719813,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:20.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294859","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294859/ownership.xml","form_type":"4"}},{"id":719815,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33404,"kind":"person","name":"Amin Dipti","position":1,"cik":"0001856708","reported_name":"Amin Dipti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:00:08.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":125000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-294852","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526294852/ownership.xml","form_type":"4"}},{"id":847445,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2026-03-12T20:05:10.000Z","date":"2026-03-12","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.625,"value":24375.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.61 to $1.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1."}],"balance_after":255516,"source":{"system":"sec-edgar","filing":"0001193125-26-104106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526104106/ownership.xml","form_type":"4"}},{"id":857022,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-07T00:51:00.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":3250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":3250000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-03-05","underlying":"Common Shares","underlying_shares":3250000},"source":{"system":"sec-edgar","filing":"0001193125-26-097185","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526097185/ownership.xml","form_type":"4"}},{"id":857021,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-07T00:50:33.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":1050000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":1050000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-03-05","underlying":"Common Shares","underlying_shares":1050000},"source":{"system":"sec-edgar","filing":"0001193125-26-097184","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526097184/ownership.xml","form_type":"4"}},{"id":857017,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-07T00:48:56.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":900000,"derivative":{"exercise_price":1.84,"expiration_date":"2036-03-05","underlying":"Common Shares","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001193125-26-097181","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526097181/ownership.xml","form_type":"4"}},{"id":906260,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-14T00:30:06.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001193125-26-052021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052021/ownership.xml","form_type":"4"}},{"id":906259,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:06.000Z","date":"2026-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12869,"price":1.8,"value":23164.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,250 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":240516,"source":{"system":"sec-edgar","filing":"0001193125-26-052021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052021/ownership.xml","form_type":"4"}},{"id":906258,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:06.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":true,"shares":31250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":253385,"source":{"system":"sec-edgar","filing":"0001193125-26-052021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052021/ownership.xml","form_type":"4"}},{"id":906263,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Restricted Stock Units","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6075},"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":906262,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2502,"price":1.8,"value":4503.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,075 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":31063,"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":906261,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2026-02-14T00:30:03.000Z","date":"2026-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6075,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":33565,"source":{"system":"sec-edgar","filing":"0001193125-26-052020","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526052020/ownership.xml","form_type":"4"}},{"id":962595,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:05.000Z","date":"2025-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":334,"price":1.68,"value":561.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 8,925 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":222135,"source":{"system":"sec-edgar","filing":"0001193125-25-327280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327280/ownership.xml","form_type":"4"}},{"id":962594,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:05.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":8925,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":222469,"source":{"system":"sec-edgar","filing":"0001193125-25-327280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327280/ownership.xml","form_type":"4"}},{"id":962593,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:03.000Z","date":"2025-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":65,"price":1.68,"value":109.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 1,735 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":27490,"source":{"system":"sec-edgar","filing":"0001193125-25-327279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327279/ownership.xml","form_type":"4"}},{"id":962592,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Shares","published_at":"2025-12-20T02:55:03.000Z","date":"2025-12-19","kind":"grant","planned":false,"acquired":true,"shares":1735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person upon the vesting of a portion of restricted stock units (\"RSUs\") granted to the Reporting Person on February 11, 2022 the vesting of which was subject to the achievement of certain performance conditions. RSUs are settled in common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in the issuer's common shares that have not vested as of the date hereof nor common shares that may be acquired upon the exercise of certain stock options outstanding as of the date hereof."}],"balance_after":27555,"source":{"system":"sec-edgar","filing":"0001193125-25-327279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000119312525327279/ownership.xml","form_type":"4"}},{"id":1093539,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33406,"kind":"person","name":"Bradsher Neal C","position":1,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"OPTION TO PURCHASE COMMON SHARES","published_at":"2025-07-03T18:45:11.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were granted to the Reporting Person by the Issuer on July 1, 2025 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable on the earlier of: (a) July 1, 2026 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the \"Issuer\") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the \"Reporting Person\") continuous service with the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"COMMON SHARES","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000919574-25-003973","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957425003973/ownership.xml","form_type":"4"}},{"id":1096710,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33404,"kind":"person","name":"Amin Dipti","position":1,"cik":"0001856708","reported_name":"Amin Dipti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:11.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093470","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093470/ownership.xml","form_type":"4"}},{"id":1096709,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:09.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093469","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093469/ownership.xml","form_type":"4"}},{"id":1096708,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:07.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093468/ownership.xml","form_type":"4"}},{"id":1096706,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:06.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093467/ownership.xml","form_type":"4"}},{"id":1096707,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":22606,"kind":"person","name":"ANDREWS DEBORAH J","position":1,"cik":"0001325697","reported_name":"ANDREWS DEBORAH J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T01:00:04.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.8977,"expiration_date":"2035-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-093466","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025093466/ownership.xml","form_type":"4"}},{"id":1210866,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-03-12T21:30:54.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":2300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":2300000,"derivative":{"exercise_price":0.53,"expiration_date":"2035-03-10","underlying":"Common Shares","underlying_shares":2300000},"source":{"system":"sec-edgar","filing":"0000950170-25-038117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025038117/ownership.xml","form_type":"4"}},{"id":1210865,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-03-12T21:30:36.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":750000,"derivative":{"exercise_price":0.53,"expiration_date":"2035-03-10","underlying":"Common Shares","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000950170-25-038116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025038116/ownership.xml","form_type":"4"}},{"id":1210864,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-03-12T21:30:11.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":750000,"derivative":{"exercise_price":0.53,"expiration_date":"2035-03-10","underlying":"Common Shares","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000950170-25-038113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025038113/ownership.xml","form_type":"4"}},{"id":1272559,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":6075,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1272558,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2440,"price":0.65,"value":1586.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":25820,"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1272557,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:08.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":28260,"source":{"system":"sec-edgar","filing":"0000950170-25-018897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018897/ownership.xml","form_type":"4"}},{"id":1272556,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-12T21:30:06.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":false,"shares":31249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":31250,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":31249},"source":{"system":"sec-edgar","filing":"0000950170-25-018887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018887/ownership.xml","form_type":"4"}},{"id":1272555,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:06.000Z","date":"2025-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12547,"price":0.65,"value":8155.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":213544,"source":{"system":"sec-edgar","filing":"0000950170-25-018887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018887/ownership.xml","form_type":"4"}},{"id":1272554,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2025-02-12T21:30:06.000Z","date":"2025-02-11","kind":"exercise","planned":false,"acquired":true,"shares":31249,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":226091,"source":{"system":"sec-edgar","filing":"0000950170-25-018887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017025018887/ownership.xml","form_type":"4"}},{"id":1293620,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrant","published_at":"2025-01-29T00:49:41.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 19, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Lineage Cell Therapeutics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire (i) 7,894,737 of the Issuer's Common Shares, no par value (the \"Common Shares\") and (ii) 7,894,737 common share purchase warrants (the \"Common Warrants\"), each of which will be exercisable for one Common Share, from the Issuer in its registered direct offering for a total purchase price of $6,000,000, or $0.76 per Common Share and accompanying Common Warrant (the \"Transaction\"). The closing of the Transaction was subject to obtaining the approval of the Issuer's shareholders, which was obtained on January 27, 2025, and the closing of the Transaction occurred on the same date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7894737,"derivative":{"exercise_price":0.91,"exercise_date":"2025-05-21","underlying":"Common Shares","underlying_shares":7894737},"source":{"system":"sec-edgar","filing":"0000919574-25-000555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957425000555/ownership.xml","form_type":"4"}},{"id":1293619,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrant","published_at":"2025-01-29T00:49:41.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":7894737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 19, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Lineage Cell Therapeutics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire (i) 7,894,737 of the Issuer's Common Shares, no par value (the \"Common Shares\") and (ii) 7,894,737 common share purchase warrants (the \"Common Warrants\"), each of which will be exercisable for one Common Share, from the Issuer in its registered direct offering for a total purchase price of $6,000,000, or $0.76 per Common Share and accompanying Common Warrant (the \"Transaction\"). The closing of the Transaction was subject to obtaining the approval of the Issuer's shareholders, which was obtained on January 27, 2025, and the closing of the Transaction occurred on the same date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7894737,"derivative":{"exercise_price":0.91,"exercise_date":"2025-05-21","underlying":"Common Shares","underlying_shares":7894737},"source":{"system":"sec-edgar","filing":"0000919574-25-000555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957425000555/ownership.xml","form_type":"4"}},{"id":1293618,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-01-29T00:49:41.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":49560992,"source":{"system":"sec-edgar","filing":"0000919574-25-000555","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957425000555/ownership.xml","form_type":"4"}},{"id":1293617,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2025-01-29T00:49:41.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":7894737,"price":0.76,"value":6000000.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On November 19, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Lineage Cell Therapeutics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire (i) 7,894,737 of the Issuer's Common Shares, no par value (the \"Common Shares\") and (ii) 7,894,737 common share purchase warrants (the \"Common Warrants\"), each of which will be exercisable for one Common Share, from the Issuer in its registered direct offering for a total purchase price of $6,000,000, or $0.76 per Common Share and accompanying Common Warrant (the \"Transaction\"). The closing of the Transaction was subject to obtaining the approval of the Issuer's shareholders, which was obtained on January 27, 2025, and the closing of the Transaction occurred on the same date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":49560992,"source":{"system":"sec-edgar","filing":"0000919574-25-000555","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957425000555/ownership.xml","form_type":"4"}},{"id":1351684,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-11-26T21:58:31.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.59,"value":8850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5925 to $0.5929, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0000950170-24-131098","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024131098/ownership.xml","form_type":"4"}},{"id":1351683,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Shares","published_at":"2024-11-26T21:55:46.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.6,"value":9000.0,"ownership":{"direct":true},"balance_after":22184,"source":{"system":"sec-edgar","filing":"0000950170-24-131093","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024131093/ownership.xml","form_type":"4"}},{"id":1353358,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2024-11-25T21:30:03.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.566,"value":22640.0,"ownership":{"direct":true},"balance_after":298555,"source":{"system":"sec-edgar","filing":"0000950170-24-130592","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024130592/ownership.xml","form_type":"4"}},{"id":1355089,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2024-11-22T14:00:04.000Z","date":"2024-11-21","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.6,"value":24000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6046 to $0.6071, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1."}],"balance_after":194842,"source":{"system":"sec-edgar","filing":"0000950170-24-129972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024129972/ownership.xml","form_type":"4"}},{"id":1430207,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2024-08-19T22:24:46.000Z","date":"2024-08-16","kind":"purchase","planned":false,"acquired":true,"shares":10500,"price":0.89,"value":9345.0,"ownership":{"direct":true},"balance_after":10500,"source":{"system":"sec-edgar","filing":"0000950170-24-098731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024098731/ownership.xml","form_type":"4"}},{"id":1461371,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:10.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081607/ownership.xml","form_type":"4"}},{"id":1461370,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:09.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081606","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081606/ownership.xml","form_type":"4"}},{"id":1461369,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":89210,"kind":"person","name":"BAILEY DON M","position":1,"cik":"0001223697","reported_name":"BAILEY DON M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:08.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081605/ownership.xml","form_type":"4"}},{"id":1461368,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:05.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081604/ownership.xml","form_type":"4"}},{"id":1461367,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":22606,"kind":"person","name":"ANDREWS DEBORAH J","position":1,"cik":"0001325697","reported_name":"ANDREWS DEBORAH J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:04.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081602/ownership.xml","form_type":"4"}},{"id":1461366,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33404,"kind":"person","name":"Amin Dipti","position":1,"cik":"0001856708","reported_name":"Amin Dipti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-03T21:00:03.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-081603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024081603/ownership.xml","form_type":"4"}},{"id":1461365,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33406,"kind":"person","name":"Bradsher Neal C","position":1,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"OPTION TO PURCHASE COMMON SHARES","published_at":"2024-07-03T18:00:10.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were granted to the Reporting Person by the Issuer on July 1, 2024 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable on July 1, 2025, provided, that Neal C. Bradsher (the \"Reporting Person\") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the \"Issuer\") on that date."}],"balance_after":75000,"derivative":{"exercise_price":0.9541,"expiration_date":"2034-07-01","underlying":"COMMON SHARES","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000919574-24-003898","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957424003898/ownership.xml","form_type":"4"}},{"id":1501056,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2024-05-28T13:11:23.000Z","date":"2024-05-24","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.05,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.05 to not more than $1.06. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":154842,"source":{"system":"sec-edgar","filing":"0000950170-24-064896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000095017024064896/ownership.xml","form_type":"4"}},{"id":1587956,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-08T21:05:31.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":1900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":1900000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-07","underlying":"Common Shares","underlying_shares":1900000},"source":{"system":"sec-edgar","filing":"0001493152-24-009382","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224009382/ownership.xml","form_type":"4"}},{"id":1587955,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-08T21:05:28.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-07","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-24-009384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224009384/ownership.xml","form_type":"4"}},{"id":1587954,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-08T21:05:26.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.13,"expiration_date":"2034-03-07","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-24-009379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224009379/ownership.xml","form_type":"4"}},{"id":1650328,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Restricted Stock Units","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 24,303 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":12151,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1650327,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2490,"price":1.08,"value":2689.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":7184,"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1650326,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:30:12.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":9674,"source":{"system":"sec-edgar","filing":"0001493152-24-005944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005944/ownership.xml","form_type":"4"}},{"id":1650325,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-13T02:27:33.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":false,"shares":31249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted 124,997 RSUs on February 11, 2022, that vested or will vest (subject to continuous service) with respect to approximately 25% of the shares subject to the award on each of February 11, 2023, 2024, 2025 and 2026."}],"balance_after":62499,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":31249},"source":{"system":"sec-edgar","filing":"0001493152-24-005942","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005942/ownership.xml","form_type":"4"}},{"id":1650324,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:27:33.000Z","date":"2024-02-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12806,"price":1.08,"value":13830.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":144842,"source":{"system":"sec-edgar","filing":"0001493152-24-005942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005942/ownership.xml","form_type":"4"}},{"id":1650323,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2024-02-13T02:27:33.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":true,"shares":31249,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date hereof or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":157648,"source":{"system":"sec-edgar","filing":"0001493152-24-005942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005942/ownership.xml","form_type":"4"}},{"id":1654313,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":89210,"kind":"person","name":"BAILEY DON M","position":1,"cik":"0001223697","reported_name":"BAILEY DON M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-02-09T00:00:09.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":96155,"price":1.04,"value":100001.2,"ownership":{"direct":false,"nature":"By The Bailey Family Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report."}],"balance_after":158801,"source":{"system":"sec-edgar","filing":"0001493152-24-005510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005510/ownership.xml","form_type":"4"}},{"id":1654312,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-02-08T23:58:18.000Z","date":"2024-02-06","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":41666255,"source":{"system":"sec-edgar","filing":"0000919574-24-000757","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957424000757/ownership.xml","form_type":"4"}},{"id":1654311,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-02-08T23:58:18.000Z","date":"2024-02-06","kind":"purchase","planned":false,"acquired":true,"shares":6730770,"price":1.04,"value":7000000.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 6, 2024, Broadwood Partners entered into a Stock Purchase Agreement with Lineage Cell Therapeutics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 6,730,770 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in its registered direct offering for a total purchase price of $7,000,000.80, or $1.04 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":41666255,"source":{"system":"sec-edgar","filing":"0000919574-24-000757","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957424000757/ownership.xml","form_type":"4"}},{"id":1697223,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2024-01-03T00:08:49.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.09,"value":10900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.08 to not more than $1.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001493152-24-000154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224000154/ownership.xml","form_type":"4"}},{"id":1840353,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:13.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023347/ownership.xml","form_type":"4"}},{"id":1840352,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":89210,"kind":"person","name":"BAILEY DON M","position":1,"cik":"0001223697","reported_name":"BAILEY DON M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:12.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023344/ownership.xml","form_type":"4"}},{"id":1840351,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33404,"kind":"person","name":"Amin Dipti","position":1,"cik":"0001856708","reported_name":"Amin Dipti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:09.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023342/ownership.xml","form_type":"4"}},{"id":1840350,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:06.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023348/ownership.xml","form_type":"4"}},{"id":1840349,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":22606,"kind":"person","name":"ANDREWS DEBORAH J","position":1,"cik":"0001325697","reported_name":"ANDREWS DEBORAH J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:02.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023343","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023343/ownership.xml","form_type":"4"}},{"id":1840348,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:46:00.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023346/ownership.xml","form_type":"4"}},{"id":1840347,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-03T21:45:57.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-23-023345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223023345/ownership.xml","form_type":"4"}},{"id":1840346,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33406,"kind":"person","name":"Bradsher Neal C","position":1,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"OPTION TO PURCHASE COMMON SHARES","published_at":"2023-07-03T20:23:54.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were granted to the Reporting Person by the Issuer on July 1, 2023 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable on July 1, 2024, provided, that Neal C. Bradsher (the \"Reporting Person\") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the \"Issuer\") on that date."}],"balance_after":50000,"derivative":{"exercise_price":1.41,"expiration_date":"2033-07-01","underlying":"COMMON SHARES","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000919574-23-003906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957423003906/ownership.xml","form_type":"4"}},{"id":1959835,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":115707,"kind":"person","name":"Hogge Gary S.","position":1,"cik":"0001771711","reported_name":"Hogge Gary S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,Clinical & Medical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-11T00:06:34.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":400000,"derivative":{"exercise_price":1.46,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001493152-23-007310","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007310/ownership.xml","form_type":"4"}},{"id":1959833,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-11T00:05:09.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":650000,"derivative":{"exercise_price":1.46,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001493152-23-007308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007308/ownership.xml","form_type":"4"}},{"id":1959832,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-11T00:03:44.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":1900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":1900000,"derivative":{"exercise_price":1.46,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":1900000},"source":{"system":"sec-edgar","filing":"0001493152-23-007306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007306/ownership.xml","form_type":"4"}},{"id":1959831,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-11T00:02:18.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":150000,"derivative":{"exercise_price":1.46,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001493152-23-007304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223007304/ownership.xml","form_type":"4"}},{"id":2017877,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:16:07.000Z","date":"2022-12-01","kind":"gift","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a gift of 25,000 common shares."}],"balance_after":5430545,"source":{"system":"sec-edgar","filing":"0001493152-23-004902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004902/ownership.xml","form_type":"5"}},{"id":2017881,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T21:15:52.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":31249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."}],"balance_after":93748,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":31249},"source":{"system":"sec-edgar","filing":"0001493152-23-004898","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004898/ownership.xml","form_type":"4"}},{"id":2017880,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:52.000Z","date":"2023-02-11","kind":"tax_withholding","acquired":false,"shares":12744,"price":1.35,"value":17204.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":126399,"source":{"system":"sec-edgar","filing":"0001493152-23-004898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004898/ownership.xml","form_type":"4"}},{"id":2017879,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:52.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":31249,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":139143,"source":{"system":"sec-edgar","filing":"0001493152-23-004898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004898/ownership.xml","form_type":"4"}},{"id":2017873,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":6076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."}],"balance_after":18227,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":6076},"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2017872,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"tax_withholding","acquired":false,"shares":2478,"price":1.35,"value":3345.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 6,076 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":3598,"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2017871,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62399,"kind":"person","name":"Samuel George A. III","position":1,"cik":"0001878732","reported_name":"Samuel George A. III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:47.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":6076,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":6076,"source":{"system":"sec-edgar","filing":"0001493152-23-004899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004899/ownership.xml","form_type":"4"}},{"id":2017876,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":115707,"kind":"person","name":"Hogge Gary S.","position":1,"cik":"0001771711","reported_name":"Hogge Gary S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,Clinical & Medical Affairs"}}],"security":"Restricted Stock Units","published_at":"2023-02-14T21:15:41.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":13020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter."}],"balance_after":39061,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":13020},"source":{"system":"sec-edgar","filing":"0001493152-23-004895","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004895/ownership.xml","form_type":"4"}},{"id":2017875,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":115707,"kind":"person","name":"Hogge Gary S.","position":1,"cik":"0001771711","reported_name":"Hogge Gary S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,Clinical & Medical Affairs"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:41.000Z","date":"2023-02-11","kind":"tax_withholding","acquired":false,"shares":5310,"price":1.35,"value":7168.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 13,020 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":7710,"source":{"system":"sec-edgar","filing":"0001493152-23-004895","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004895/ownership.xml","form_type":"4"}},{"id":2017874,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":115707,"kind":"person","name":"Hogge Gary S.","position":1,"cik":"0001771711","reported_name":"Hogge Gary S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,Clinical & Medical Affairs"}}],"security":"Common Shares, no par value","published_at":"2023-02-14T21:15:41.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":13020,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units (\"RSUs\") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options."}],"balance_after":13020,"source":{"system":"sec-edgar","filing":"0001493152-23-004895","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223004895/ownership.xml","form_type":"4"}},{"id":2115275,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":62400,"kind":"person","name":"Howe Jill Ann","position":1,"cik":"0001892397","reported_name":"Howe Jill Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-11-16T21:17:31.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to one quarter of the shares subject to the option on November 14, 2023, and the balance will vest in 36 successive substantially equal installments thereafter, subject to the reporting person's continuous employment."}],"balance_after":1000000,"derivative":{"exercise_price":1.36,"expiration_date":"2032-11-14","underlying":"Common Shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-22-032631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222032631/ownership.xml","form_type":"4"}},{"id":2213197,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33403,"kind":"person","name":"Russell Angus C.","position":1,"cik":"0001534002","reported_name":"Russell Angus C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:16:02.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018685/ownership.xml","form_type":"4"}},{"id":2213196,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":22606,"kind":"person","name":"ANDREWS DEBORAH J","position":1,"cik":"0001325697","reported_name":"ANDREWS DEBORAH J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:58.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018684","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018684/ownership.xml","form_type":"4"}},{"id":2213194,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33407,"kind":"person","name":"Jayasuriya Anula","position":1,"cik":"0001822933","reported_name":"Jayasuriya Anula","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:54.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018683/ownership.xml","form_type":"4"}},{"id":2213193,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33405,"kind":"person","name":"Mulroy Michael H.","position":1,"cik":"0001509725","reported_name":"Mulroy Michael H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:50.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018682","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018682/ownership.xml","form_type":"4"}},{"id":2213192,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:46.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018681/ownership.xml","form_type":"4"}},{"id":2213195,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":89210,"kind":"person","name":"BAILEY DON M","position":1,"cik":"0001223697","reported_name":"BAILEY DON M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:42.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018680/ownership.xml","form_type":"4"}},{"id":2213191,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33406,"kind":"person","name":"Bradsher Neal C","position":1,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"OPTION TO PURCHASE COMMON SHARES","published_at":"2022-07-06T20:15:34.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options were granted to the Reporting Person by the Issuer on July 1, 2022 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options will vest and become exercisable on July 1, 2023, provided, that Neal C. Bradsher (the \"Reporting Person\") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the \"Issuer\") on that date."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"COMMON SHARES","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000919574-22-004056","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000091957422004056/ownership.xml","form_type":"4"}},{"id":2213190,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":33404,"kind":"person","name":"Amin Dipti","position":1,"cik":"0001856708","reported_name":"Amin Dipti","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T20:15:31.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer."}],"balance_after":50000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-01","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-22-018687","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018687/ownership.xml","form_type":"4"}},{"id":2218945,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-06-30T21:57:05.000Z","date":"2022-06-30","kind":"exercise","acquired":false,"shares":15450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15450},"source":{"system":"sec-edgar","filing":"0001493152-22-018271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018271/ownership.xml","form_type":"4"}},{"id":2218944,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2022-06-30T21:57:05.000Z","date":"2022-06-30","kind":"tax_withholding","acquired":false,"shares":5343,"price":1.58,"value":8441.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report."}],"balance_after":107894,"source":{"system":"sec-edgar","filing":"0001493152-22-018271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018271/ownership.xml","form_type":"4"}},{"id":2218943,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares, no par value","published_at":"2022-06-30T21:57:05.000Z","date":"2022-06-30","kind":"exercise","acquired":true,"shares":15450,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units (\"RSUs\") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units (\"RSUs\") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report."}],"balance_after":113237,"source":{"system":"sec-edgar","filing":"0001493152-22-018271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222018271/ownership.xml","form_type":"4"}},{"id":2309747,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":61382,"kind":"person","name":"Culley Brian M","position":1,"cik":"0001310683","reported_name":"Culley Brian M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-04-04T20:05:36.000Z","date":"2022-03-31","kind":"exercise","acquired":false,"shares":15450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter."}],"balance_after":15450,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":15450},"source":{"system":"sec-edgar","filing":"0001493152-22-009000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222009000/ownership.xml","form_type":"4"}}],"next_cursor":"2022-04-04T20:05:36.000000Z,2309747"}